What is SigTuple?
Headquartered in Bengaluru, India, and established in 2015, SigTuple specializes in the development of intelligent screening solutions that leverage artificial intelligence to analyze visual medical data. By automating complex diagnostic processes, the company aims to enhance the accuracy and efficiency of medical screenings, thereby addressing critical gaps in healthcare delivery. SigTuple operates at the intersection of deep tech and clinical diagnostics, providing scalable tools that empower healthcare providers to deliver faster, more reliable patient outcomes. Its market position is bolstered by a robust portfolio of intellectual property and a clear focus on high-impact medical applications.
How much funding has SigTuple raised?
SigTuple has raised a total of $52.1M across 4 funding rounds:
Series A
$5.8M
Series B
$19M
Series C
$23.3M
Series C
$4M
Series A (2017): $5.8M with participation from Pi Ventures, Accel Partners, IDG Capital, Endiya Partners, and Axilor Ventures
Series B (2018): $19M led by Trifecta Capital Services, Accel, Ridge Ventures, Binny Bansal, Endiya Partners, Axilor Ventures, Venture Highway, and pi Ventures
Series C (2023): $23.3M supported by Endiya Partners, Chiratae Ventures, Pi Ventures, Trifecta Capital Services, Accel Partners, Binny Bansal, and Trusted Insights
Series C (2024): $4M featuring Endiya Partners and SIDBI Venture Capital
Key Investors in SigTuple
Endiya Partners
Endiya Partners is an early-stage venture capital fund that focuses on investing in Indian product startups within the sectors of enterprise, industrial technology, healthcare, and life sciences.
Pi Ventures
Pi Ventures is a venture capital firm that focuses its investments in companies that develop artificial intelligence, machine learning and IoT.
Chiratae Ventures
Chiratae Ventures is an established Indian technology venture capital fund advisor based in Bengaluru, managing significant assets across multiple funds with a strong track record in supporting unicorns.
What's next for SigTuple?
With the recent capital injection, SigTuple is well-positioned to transition into its next phase of enterprise-level scaling. The company is expected to prioritize the expansion of its AI diagnostic platform into new international markets while deepening its research and development capabilities. By leveraging the strategic backing of its seasoned investor base, SigTuple will likely focus on enhancing its product suite to meet the evolving demands of global healthcare systems, ensuring that its diagnostic tools remain at the forefront of clinical innovation and operational excellence.
See full SigTuple company page
